Trump tax reform uncertainty puts biotech M&A on hold
Tesaro and Puma are potential takeover targets
X
Trump tax reform uncertainty puts biotech M&A on hold
https://pharmaphorum.com/news/uncertainty-trump-tax-reforms-puts-biotech-ma-hold/
Puma
Victory for Puma as FDA approves breast cancer drug
Neratinib can be used to reduce risk of disease returning.
Puma gains as Roche breast cancer combo disappoints
ASCO serves up shock as Roche’s data disappoints
FDA advisers back Puma breast cancer drug despite safety worries
But biotech still has several hurdles to clear – including Roche’s rival.
Roche breast cancer trial success could kill Puma’s rival
Perjeta trial success sends rival biotech’s share price crashing.
